Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events) "CANTOS"

Recruiting

Phase 3 Results N/A

Summary of Purpose

Main Study (CACZ885M2301) The purpose of this trial is to test the hypothesis that canakinumab treatment of patients with MI at least one month prior to study entry and elevated hsCRP will prevent recurrent cardiovascular events. Sub-study 1 (CACZ885M2301S1) The purpose of this sub-study is to evaluate the effect of quarterly subcutaneous canakinumab treatment for 24 months comparted with placebo on the ...

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 1 April 2013.

1 Apr 2011 29 Mar 2011 1 Jul 2016 1 Jul 2016 1 Apr 2013 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Basics

Interventions

Conditions

Sponsors

Trial Design

  • Allocation: Randomized
  • Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
  • Purpose: Treatment
  • Endpoint: Safety/Efficacy Study
  • Intervention: Parallel Assignment

Contacts

  • Novartis Pharmaceuticals